Patents Examined by Sean Basquill
-
Patent number: 8557867Abstract: Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SUR1 and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant.Type: GrantFiled: June 20, 2008Date of Patent: October 15, 2013Assignees: The United States of America as Represented by the Department of Veterans Affairs, University of Maryland, BaltimoreInventor: J. Marc Simard
-
Patent number: 8546569Abstract: The use of a compound of formula I Y is a single bond, C?O, C?S or S(O)m where m is 0, 1 or 2; the ring is a 6 membered aromatic ring or is a 5 or 6 membered heteroaromatic ring; Z and Z? are provided that both are not N; R1, R2, R3, R3a, R4, R8 and Ra are specified organic groups and n and p are independently 0, 1, 2, 3 or 4; or salts or N-oxides thereof or compositions containing them in controlling insects, acarines, nematodes or molluscs. Novel compounds are also provided.Type: GrantFiled: February 10, 2012Date of Patent: October 1, 2013Assignee: Syngenta Crop Protection, Inc.Inventors: Peter Maienfisch, Louis-Pierre Molleyres, Jerome Cassayre, Fredrik Cederbaum, Camilla Corsi, Thomas Pitterna
-
Patent number: 8541468Abstract: There are provided an ophthalmic composition that comprises 3-hydroxybutyric acid and/or salts thereof as active ingredients and is used to prevent desiccation of eyes and an ophthalmic composition that is used to treat tear dysfunction. By use of the ophthalmic compositions of the present invention, desiccation of the eyes can be inhibited and tear dysfunction can be treated. Therefore, by use of the compositions, discomforts caused by tear dysfunction, such as desiccation of the eyes, foreign-body sensation, feeling of discomfort on the eyes and eye strain, can be improved. Further, the ophthalmic compositions of the present invention can inhibit diseases caused by tear dysfunction, exemplified by development of dry eye and suspected dry eye which are dysfunctions related to desiccation of the eyes, particularly, development of diseases caused by tear dysfunction without injuries on the keratoconjunctive.Type: GrantFiled: September 30, 2004Date of Patent: September 24, 2013Assignee: Ophtecs CorporationInventors: Yuzuru Umeda, Hideo Nakashima, Michiko Shibuya, Yasukazu Saitoh, Shoji Okada, Shigeru Nakamura
-
Patent number: 8536212Abstract: The present invention provides a protective agent for retinal nerve or optic nerve which exerts its effect through a different mechanism from that of conventional therapeutic agents and can be taken for long periods. The present invention is the protective agent for retinal nerve or optic nerve which comprises a compound with aldose reductase inhibiting activity such as the compound represented by the following general formula as an active ingredient. A preferable compound thereof is (2S,4S)-6-fluoro-2?,5?-dioxospiro[chroman-4,4?-imidazolidine]-2-carboxamide: wherein X represents a halogen atom or a hydrogen atom, R1 and R2 independently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto, or optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle.Type: GrantFiled: January 30, 2008Date of Patent: September 17, 2013Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Sookja Kim Chung, Stephen Chung, Chihiro Hibi
-
Patent number: 8535713Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. 10].Type: GrantFiled: April 4, 2008Date of Patent: September 17, 2013Assignee: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Patent number: 8513437Abstract: The invention provides pyrrolidino-substituted 1,4-naphthoquinone derivatives that modulate the activity of protein kinases, and it relates to the use of the derivatives in pharmaceutical compositions for treating cardiovascular disorders and malignancies. The invention particularly provides medicaments for treating disorders associated with MAPKs signaling, ERKs signaling, p38 signaling, and JNKs signaling.Type: GrantFiled: July 21, 2005Date of Patent: August 20, 2013Assignee: Ben Gurion University of the Negev Research and Development AuthorityInventors: Yossi Granot, Shmuel Bittner
-
Patent number: 8466203Abstract: A method for stabilizing collagenous eye tissues by nitrite and nitroalcohol treatment. The topical stiffening agent contains sodium nitrite or a nitroalcohol in a buffered balanced salt solution and can be applied to the surface of the eye on a daily basis for a prolonged period. Application of the solution results in progressive stabilization of the corneal and scleral tissues through non-enzymatic cross-linking of collagen fibers. The compounds can penetrate into the corneal stroma without the need to remove the corneal epithelium. In addition, ultraviolet light is not needed to activate the cross-linking process. The resulting stabilization of corneal and scleral tissues can prevent future alterations in corneal curvature and has utility in diseases such as keratoconus, keratectasia, progressive myopia, and glaucoma.Type: GrantFiled: December 6, 2007Date of Patent: June 18, 2013Inventors: David Choohyun Paik, Stephen Lewis Trokel
-
Patent number: 8455662Abstract: Formulations are provided, comprising: a compound of Formula I, a pharmaceutically acceptable salt thereof, or a mixture of any two or more thereof; and an ingredient selected from a hydrophilic solvent, a lipophilic solvent, an emulsifier, or a mixture of any two or more thereof; wherein the compound of Formula I is: In some embodiments, the formulations are liquids. In other embodiments, the formulations are solids. Also provided are methods of preparing such formulations.Type: GrantFiled: July 20, 2007Date of Patent: June 4, 2013Assignee: Novartis AGInventors: Ahmad Hashash, Sean Ritchie, Kangwen Lin, Peng Shen, Augustus Okhamafe, Rampurna Gullapalli
-
Patent number: 8455526Abstract: The invention discloses the use of 2-butyl-4-chloro-1-[2?-(1H-tetrazol-5-yl)1,1?-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxycarbonyl)oxy] methyl ester and the pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of the damage of a target organ caused by hypertension. It particularly discloses the use of this compound in the manufacture of a medicament for the treatment of left ventricular hypertrophy, renal dysfunction, aorta thickening caused by hypertension, which provides an effective drug and method for the treatment of the damage of target organs for hypertension patients.Type: GrantFiled: June 6, 2008Date of Patent: June 4, 2013Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventor: Jianhui Guo
-
Patent number: 8445678Abstract: Disclosed are 2-quinoxalinol salen compounds and in particular 2-quinoxalinol salen Schiff-base ligands. The disclosed 2-quinoxalinol salen compounds may be utilized as ligands for forming complexes with cations, and further, the formed complexes may be utilized as catalysts for oxidation reactions. The disclosed 2-quinoxalinol salen compounds also may be conjugated to solid supports and utilized in methods for selective solid-phase extraction or detection of cations.Type: GrantFiled: October 11, 2011Date of Patent: May 21, 2013Assignee: Auburn UniversityInventors: Anne E. V. Gorden, Xianghong Wu
-
Patent number: 8440194Abstract: Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.Type: GrantFiled: February 19, 2008Date of Patent: May 14, 2013Assignee: Celgene CorporationInventor: Jerome B. Zeldis
-
Patent number: 8425879Abstract: Nanovectors are disclosed that make it possible to simultaneously target, image, and treat cancerous cells using photodynamic therapy. Also disclosed are novel molecules (I) derived from porphyrins, silica-based nanoparticles comprising the same, and their use in photodynamic therapy.Type: GrantFiled: September 14, 2009Date of Patent: April 23, 2013Assignees: Centre National de la Recherche Scientifique, Institut Curie, Universite Mouloud Mammeri, Universite Montpellier 2Inventors: David Brevet, Ouahiba Hocine, Jean-Olivier Durand, Philippe Maillard, Alain Morere, Marcel Garcia, Monique Smaïhi, Magali Gary-Bobo
-
Patent number: 8420637Abstract: The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R1 and R2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.Type: GrantFiled: September 22, 2009Date of Patent: April 16, 2013Assignee: Allergan, Inc.Inventors: June Chen, Simon Pettit, Hans Fliri
-
Patent number: 8409606Abstract: An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline.Type: GrantFiled: February 12, 2010Date of Patent: April 2, 2013Assignee: Incept, LLCInventors: Amarpreet S. Sawhney, Peter Jarrett, Michael Bassett, Charles Blizzard
-
Patent number: 8394845Abstract: Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs.Type: GrantFiled: May 11, 2011Date of Patent: March 12, 2013Assignee: Hanall Biopharma Co., Ltd.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jae Woon Son
-
Patent number: 8394364Abstract: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.Type: GrantFiled: July 28, 2010Date of Patent: March 12, 2013Assignee: CLS Pharmaceuticals, Inc.Inventors: C. Michael Samson, Bo Liang, Joseph A. Capriotti
-
Patent number: 8372980Abstract: Fused-ring, heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein ?represents an optional double bond, and wherein An, En, Mn, Gn, Jn, R3, n7, R8, R9, R10, R11, R32, R33, X, Y, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.Type: GrantFiled: July 22, 2011Date of Patent: February 12, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Mariappan V. Chelliah, Samuel Chackalamannil
-
Patent number: 8372387Abstract: The invention provides a therapeutic composition comprising an aqueous buffer, and a therapeutic agent that improves the functioning of a diseased heart by decreasing left ventricular end-diastolic pressure and simultaneously increasing left ventricular ejection without affecting the blood pressure or heart rate.Type: GrantFiled: April 4, 2008Date of Patent: February 12, 2013Assignee: Phrixus Pharmaceuticals, Inc.Inventor: Bruce Edward Markham
-
Patent number: 8367097Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.Type: GrantFiled: May 12, 2010Date of Patent: February 5, 2013Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
-
Patent number: 8338403Abstract: A compound having a hyperglycemia improving effect and a hemoglobin A1c lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.Type: GrantFiled: June 1, 2010Date of Patent: December 25, 2012Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Ryuuichi Higuchi, Masanori Inagaki, Hirotoshi Hayasawa, Muneo Yamada, Miyuki Tanaka, Eriko Misawa, Noriko Wakimoto, Yousuke Itou